Papers associated with grin2c

???displayGene.coCitedPapers???

???pagination.result.count???

???pagination.result.page??? 1 2 ???pagination.result.next???

Sort Newest To Oldest

Sort Oldest To Newest

	Subunit-specific effects of poricoic acid A on NMDA receptors., Lee J, Kim C, Yeom HD, Nguyen KVA, Eom S, Lee S, Jung JH, Lee JH, Kim SH, Kim IK, Lee JH, Lee JH., Pharmacol Rep. April 1, 2020; 72 (2): 472-480.
	An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups., Perszyk R, Katzman BM, Kusumoto H, Kell SA, Epplin MP, Tahirovic YA, Moore RL, Menaldino D, Burger P, Liotta DC, Traynelis SF., Elife. May 24, 2018; 7
	The neuroactive steroid pregnenolone sulfate stimulates trafficking of functional N-methyl D-aspartate receptors to the cell surface via a noncanonical, G protein, and Ca2+-dependent mechanism., Kostakis E, Smith C, Jang MK, Martin SC, Richards KG, Russek SJ, Gibbs TT, Farb DH., Mol Pharmacol. August 1, 2013; 84 (2): 261-74.
	A steroid modulatory domain in NR2A collaborates with NR1 exon-5 to control NMDAR modulation by pregnenolone sulfate and protons., Kostakis E, Jang MK, Russek SJ, Gibbs TT, Farb DH., J Neurochem. November 1, 2011; 119 (3): 486-96.
	Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists., Mosley CA, Acker TM, Hansen KB, Mullasseril P, Andersen KT, Le P, Vellano KM, Bräuner-Osborne H, Liotta DC, Traynelis SF., J Med Chem. August 12, 2010; 53 (15): 5476-90.
	Characterization of conantokin Rl-A: molecular phylogeny as structure/function study., Gowd KH, Watkins M, Twede VD, Bulaj GW, Olivera BM., J Pept Sci. August 1, 2010; 16 (8): 375-82.
	Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors., Dravid SM, Burger PB, Prakash A, Geballe MT, Yadav R, Le P, Vellano K, Snyder JP, Traynelis SF., J Neurosci. February 17, 2010; 30 (7): 2741-54.
	N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse., Costa BM, Feng B, Tsintsadze TS, Morley RM, Irvine MW, Tsintsadze V, Lozovaya NA, Jane DE, Monaghan DT., J Pharmacol Exp Ther. November 1, 2009; 331 (2): 618-26.
	Control of NMDA receptor function by the NR2 subunit amino-terminal domain., Yuan H, Hansen KB, Vance KM, Ogden KK, Traynelis SF., J Neurosci. September 30, 2009; 29 (39): 12045-58.
	Stereocontrolled synthesis and pharmacological evaluation of azetidine-2,3-dicarboxylic acids at NMDA receptors., Sivaprakasam M, Hansen KB, David O, Nielsen B, Traynelis SF, Clausen RP, Couty F, Bunch L., ChemMedChem. January 1, 2009; 4 (1): 110-7.
	Differential effects of linear and cyclic polyamines on NMDA receptor activities., Masuko T, Miyake M, Kusama-Eguchi K, Koike T, Kimura E, Kizawa Y, Kashiwagi K, Igarashi K, Kusama T., Neurochem Int. July 1, 2008; 53 (1-2): 38-44.
	Subunit-specific agonist activity at NR2A-, NR2B-, NR2C-, and NR2D-containing N-methyl-D-aspartate glutamate receptors., Erreger K, Geballe MT, Kristensen A, Chen PE, Hansen KB, Lee CJ, Lee CJ, Yuan H, Le P, Lyuboslavsky PN, Micale N, Jørgensen L, Clausen RP, Wyllie DJ, Snyder JP, Traynelis SF., Mol Pharmacol. October 1, 2007; 72 (4): 907-20.
	Subunit-specific contribution of pore-forming domains to NMDA receptor channel structure and gating., Sobolevsky AI, Prodromou ML, Yelshansky MV, Wollmuth LP., J Gen Physiol. June 1, 2007; 129 (6): 509-25.
	Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block., Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, Almonte A, Murray E, Mosely C, Barber J, French A, Balster R, Murray TF, Traynelis SF., J Physiol. May 15, 2007; 581 (Pt 1): 107-28.
	Synthesis, binding affinity at glutamic acid receptors, neuroprotective effects, and molecular modeling investigation of novel dihydroisoxazole amino acids., Conti P, De Amici M, Grazioso G, Roda G, Pinto A, Hansen KB, Nielsen B, Madsen U, Bräuner-Osborne H, Egebjerg J, Vestri V, Pellegrini-Giampietro DE, Sibille P, Acher FC, De Micheli C., J Med Chem. October 6, 2005; 48 (20): 6315-25.
	Identification of subunit- and antagonist-specific amino acid residues in the N-Methyl-D-aspartate receptor glutamate-binding pocket., Kinarsky L, Feng B, Skifter DA, Morley RM, Sherman S, Jane DE, Monaghan DT., J Pharmacol Exp Ther. June 1, 2005; 313 (3): 1066-74.
	Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists., Morley RM, Tse HW, Feng B, Miller JC, Monaghan DT, Jane DE., J Med Chem. April 7, 2005; 48 (7): 2627-37.
	The effect of competitive antagonist chain length on NMDA receptor subunit selectivity., Feng B, Morley RM, Jane DE, Monaghan DT., Neuropharmacology. March 1, 2005; 48 (3): 354-9.
	The micromolar zinc-binding domain on the NMDA receptor subunit NR2B., Rachline J, Perin-Dureau F, Le Goff A, Neyton J, Paoletti P., J Neurosci. January 12, 2005; 25 (2): 308-17.
	Characterization of two novel N-methyl-D-aspartate antagonists: EAA-090 (2-[8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en2-yl]ethylphosphonic acid) and EAB-318 (R-alpha-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid hydrochloride)., Sun L, Chiu D, Kowal D, Simon R, Smeyne M, Zukin RS, Olney J, Baudy R, Lin S., J Pharmacol Exp Ther. August 1, 2004; 310 (2): 563-70.
	Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid., Feng B, Tse HW, Skifter DA, Morley R, Jane DE, Monaghan DT., Br J Pharmacol. February 1, 2004; 141 (3): 508-16.
	Clozapine inhibits isolated N-methyl-D-aspartate receptors expressed in xenopus oocytes in a subunit specific manner., Levine JB, Martin G, Wilson A, Treistman SN., Neurosci Lett. August 7, 2003; 346 (3): 125-8.
	Staggering of subunits in NMDAR channels., Sobolevsky AI, Rooney L, Wollmuth LP., Biophys J. December 1, 2002; 83 (6): 3304-14.
	N-Methyl-D-aspartate receptor subtype-selectivity of homoquinolinate: an electrophysiological and radioligand binding study using both native and recombinant receptors., Grimwood S, Wafford KA, Macaulay A, Hutson PH., J Neurochem. August 1, 2002; 82 (4): 794-800.
	Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids., Malayev A, Gibbs TT, Farb DH., Br J Pharmacol. February 1, 2002; 135 (4): 901-9.
	Specificity of putative partial agonist, 1-aminocyclopropanecarboxylic acid, for rat N-methyl-D-aspartate receptor subunits., Sheinin A, Nahum-Levy R, Shavit S, Benveniste M., Neurosci Lett. January 11, 2002; 317 (2): 77-80.
	Lead inhibition of NMDA channels in native and recombinant receptors., Gavazzo P, Gazzoli A, Mazzolini M, Marchetti C., Neuroreport. October 8, 2001; 12 (14): 3121-5.
	Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine., Sheinin A, Shavit S, Benveniste M., Neuropharmacology. August 1, 2001; 41 (2): 151-8.
	High-affinity Zn block in recombinant N-methyl-D-aspartate receptors with cysteine substitutions at the Q/R/N site., Amar M, Perin-Dureau F, Neyton J., Biophys J. July 1, 2001; 81 (1): 107-16.
	Evidence for direct protein kinase-C mediated modulation of N-methyl-D-aspartate receptor current., Liao GY, Wagner DA, Hsu MH, Leonard JP., Mol Pharmacol. May 1, 2001; 59 (5): 960-4.
	Four residues of the extracellular N-terminal domain of the NR2A subunit control high-affinity Zn2+ binding to NMDA receptors., Fayyazuddin A, Villarroel A, Le Goff A, Lerma J, Neyton J., Neuron. March 1, 2000; 25 (3): 683-94.
	In vitro and in vivo characterization of conantokin-R, a selective NMDA receptor antagonist isolated from the venom of the fish-hunting snail Conus radiatus., White HS, McCabe RT, Armstrong H, Donevan SD, Cruz LJ, Abogadie FC, Torres J, Rivier JE, Paarmann I, Hollmann M, Olivera BM., J Pharmacol Exp Ther. January 1, 2000; 292 (1): 425-32.
	Stimulatory and inhibitory properties of aminoglycoside antibiotics at N-methyl-D-aspartate receptors., Masuko T, Kuno T, Kashiwagi K, Kusama T, Williams K, Igarashi K., J Pharmacol Exp Ther. September 1, 1999; 290 (3): 1026-33.
	Structure-activity relationship of N-(phenylalkyl)cinnamides as novel NR2B subtype-selective NMDA receptor antagonists., Tamiz AP, Cai SX, Zhou ZL, Yuen PW, Schelkun RM, Whittemore ER, Weber E, Woodward RM, Keana JF., J Med Chem. August 26, 1999; 42 (17): 3412-20.
	NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A., Goebel DJ, Poosch MS., Brain Res Mol Brain Res. June 8, 1999; 69 (2): 164-70.
	The human N-methyl-D-aspartate receptor 2C subunit: genomic analysis, distribution in human brain, and functional expression., Daggett LP, Johnson EC, Varney MA, Lin FF, Hess SD, Deal CR, Jachec C, Lu CC, Kerner JA, Landwehrmeyer GB, Standaert DG, Young AB, Harpold MM, Veliçelebi G., J Neurochem. November 1, 1998; 71 (5): 1953-68.
	Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors., Tamiz AP, Whittemore ER, Zhou ZL, Huang JC, Drewe JA, Chen JC, Cai SX, Weber E, Woodward RM, Keana JF., J Med Chem. August 27, 1998; 41 (18): 3499-506.
	Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit., Traynelis SF, Burgess MF, Zheng F, Lyuboslavsky P, Powers JL., J Neurosci. August 15, 1998; 18 (16): 6163-75.
	Differentiation of glycine antagonist sites of N-methyl-D-aspartate receptor subtypes. Preferential interaction of CGP 61594 with NR1/2B receptors., Honer M, Benke D, Laube B, Kuhse J, Heckendorn R, Allgeier H, Angst C, Monyer H, Seeburg PH, Betz H, Mohler H., J Biol Chem. May 1, 1998; 273 (18): 11158-63.
	An active-site histidine of NR1/2C mediates voltage-independent inhibition by zinc., Gray AT, Leonoudakis DJ, Yost CS., Brain Res Mol Brain Res. December 1, 1997; 52 (1): 157-61.
	Benzyl-polyamines: novel, potent N-methyl-D-aspartate receptor antagonists., Igarashi K, Shirahata A, Pahk AJ, Kashiwagi K, Williams K., J Pharmacol Exp Ther. November 1, 1997; 283 (2): 533-40.
	Lead inhibition of N-methyl-D-aspartate receptors containing NR2A, NR2C and NR2D subunits., Omelchenko IA, Nelson CS, Allen CN., J Pharmacol Exp Ther. September 1, 1997; 282 (3): 1458-64.
	Pharmacological heterogeneity of NMDA receptors: characterization of NR1a/NR2D heteromers expressed in Xenopus oocytes., Buller AL, Monaghan DT., Eur J Pharmacol. February 5, 1997; 320 (1): 87-94.
	NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology., Monaghan DT, Larsen H., J Pharmacol Exp Ther. February 1, 1997; 280 (2): 614-20.
	Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol., Ilyin VI, Whittemore ER, Guastella J, Weber E, Woodward RM., Mol Pharmacol. December 1, 1996; 50 (6): 1541-50.
	Structure of the NMDA receptor channel M2 segment inferred from the accessibility of substituted cysteines., Kuner T, Wollmuth LP, Karlin A, Seeburg PH, Sakmann B., Neuron. August 1, 1996; 17 (2): 343-52.
	Multiple structural elements determine subunit specificity of Mg2+ block in NMDA receptor channels., Kuner T, Schoepfer R., J Neurosci. June 1, 1996; 16 (11): 3549-58.
	The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits., de Carvalho LP, Bochet P, Rossier J., Neurochem Int. April 1, 1996; 28 (4): 445-52.
	Glycine modulates ethanol inhibition of heteromeric N-methyl-D-aspartate receptors expressed in Xenopus oocytes., Buller AL, Larson HC, Morrisett RA, Monaghan DT., Mol Pharmacol. October 1, 1995; 48 (4): 717-23.
	Ethanol inhibition of recombinant heteromeric NMDA channels in the presence and absence of modulators., Chu B, Anantharam V, Treistman SN., J Neurochem. July 1, 1995; 65 (1): 140-8.

???pagination.result.page??? 1 2 ???pagination.result.next???